Foresee Pharmaceuticals Co Ltd (6576) - Net Assets
Based on the latest financial reports, Foresee Pharmaceuticals Co Ltd (6576) has net assets worth NT$971.84 Million TWD (≈ $30.62 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.57 Billion ≈ $49.33 Million USD) and total liabilities (NT$593.99 Million ≈ $18.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Foresee Pharmaceuticals Co Ltd (6576) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$971.84 Million |
| % of Total Assets | 62.07% |
| Annual Growth Rate | 14.93% |
| 5-Year Change | -12.59% |
| 10-Year Change | N/A |
| Growth Volatility | 49.47 |
Foresee Pharmaceuticals Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Foresee Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. See Foresee Pharmaceuticals Co Ltd (6576) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Foresee Pharmaceuticals Co Ltd (2017–2024)
The table below shows the annual net assets of Foresee Pharmaceuticals Co Ltd from 2017 to 2024. For live valuation and market cap data, see 6576 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.60 Billion ≈ $50.38 Million |
+28.48% |
| 2023-12-31 | NT$1.24 Billion ≈ $39.21 Million |
+36.67% |
| 2022-12-31 | NT$910.58 Million ≈ $28.69 Million |
-31.03% |
| 2021-12-31 | NT$1.32 Billion ≈ $41.59 Million |
-27.83% |
| 2020-12-31 | NT$1.83 Billion ≈ $57.63 Million |
+104.19% |
| 2019-12-31 | NT$895.86 Million ≈ $28.22 Million |
+79.67% |
| 2018-12-31 | NT$498.62 Million ≈ $15.71 Million |
-17.40% |
| 2017-12-31 | NT$603.66 Million ≈ $19.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Foresee Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 470871900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$7.41 Billion | 463.39% |
| Total Equity | NT$1.60 Billion | 100.00% |
Foresee Pharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Foresee Pharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Tractor Company Limited
F:FTP
|
$391.78 Million |
|
Kretam Holdings Bhd
KLSE:1996
|
$391.83 Million |
|
Djurslands Bank
CO:DJUR
|
$391.96 Million |
|
WPG (Shanghai) Smart Water Public Co. Ltd
SHG:603956
|
$391.96 Million |
|
GDI Integrated
TO:GDI
|
$391.59 Million |
|
Qingdao Richmat Intelligence Technology Co. Ltd. A
SHE:301320
|
$391.25 Million |
|
Samji Electronics Co. Ltd
KQ:037460
|
$391.25 Million |
|
Y mAbs Therapeutics
NASDAQ:YMAB
|
$391.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Foresee Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,244,512,000 to 1,599,000,000, a change of 354,488,000 (28.5%).
- Net loss of 1,081,072,000 reduced equity.
- New share issuances of 1,377,635,000 increased equity.
- Other factors increased equity by 57,925,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.08 Billion | -67.61% |
| Share Issuances | NT$1.38 Billion | +86.16% |
| Other Changes | NT$57.92 Million | +3.62% |
| Total Change | NT$- | 28.48% |
Book Value vs Market Value Analysis
This analysis compares Foresee Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.85x to 7.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$7.28 | NT$79.00 | x |
| 2018-12-31 | NT$5.45 | NT$79.00 | x |
| 2019-12-31 | NT$8.79 | NT$79.00 | x |
| 2020-12-31 | NT$17.84 | NT$79.00 | x |
| 2021-12-31 | NT$11.12 | NT$79.00 | x |
| 2022-12-31 | NT$7.71 | NT$79.00 | x |
| 2023-12-31 | NT$9.78 | NT$79.00 | x |
| 2024-12-31 | NT$10.33 | NT$79.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Foresee Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -258.20%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.35x
- Recent ROE (-67.61%) is below the historical average (-64.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -73.47% | -1869.28% | 0.03x | 1.16x | NT$-503.85 Million |
| 2018 | -110.61% | -2118.28% | 0.04x | 1.25x | NT$-601.38 Million |
| 2019 | -54.39% | -647.91% | 0.07x | 1.13x | NT$-576.80 Million |
| 2020 | -27.92% | -221.63% | 0.11x | 1.15x | NT$-693.64 Million |
| 2021 | -43.12% | -251.86% | 0.14x | 1.24x | NT$-701.28 Million |
| 2022 | -51.91% | -156.76% | 0.23x | 1.43x | NT$-563.70 Million |
| 2023 | -83.27% | -531.33% | 0.10x | 1.50x | NT$-1.16 Billion |
| 2024 | -67.61% | -258.20% | 0.19x | 1.35x | NT$-1.24 Billion |
Industry Comparison
This section compares Foresee Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,032,347,900
- Average return on equity (ROE) among peers: 4.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Foresee Pharmaceuticals Co Ltd (6576) | NT$971.84 Million | -73.47% | 0.61x | $391.65 Million |
| Grape King Bio Ltd (1707) | $1.74 Billion | 9.43% | 0.48x | $462.98 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $3.12 Billion | 7.90% | 0.56x | $352.43 Million |
| Maywufa Co Ltd (1731) | $1.47 Billion | 5.23% | 0.78x | $90.87 Million |
| ScinoPharm Taiwan Ltd (1789) | $8.56 Billion | 11.21% | 0.11x | $499.50 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $1.49 Billion | 0.80% | 0.34x | $1.58 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $44.35 Million |
| LIWANLI Innovation Co Ltd (3054) | $1.51 Billion | 4.15% | 0.15x | $172.02 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $478.34 Million |
| TTY Biopharm Co Ltd (4105) | $5.77 Billion | 14.42% | 0.61x | $577.35 Million |
| Phytohealth Corp (4108) | $1.56 Billion | -10.88% | 0.06x | $75.40 Million |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more